Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2011 1
2012 2
2013 1
2014 3
2015 2
2019 1
2020 1
2021 3
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean michele susani (3 results)?
Biologic tools to personalize treatment in genitourinary cancers.
Bracarda S, Sisani M, Del Buono S, Ishiwa O, Montagnani F; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Bracarda S, et al. Among authors: sisani m. Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e42-8. doi: 10.1016/j.critrevonc.2010.09.008. Epub 2011 Jan 12. Crit Rev Oncol Hematol. 2012. PMID: 21232974 Review.
Results of the observational prospective RealFLOT study.
Giommoni E, Lavacchi D, Tirino G, Fornaro L, Iachetta F, Pozzo C, Satolli MA, Spallanzani A, Puzzoni M, Stragliotto S, Sisani M, Formica V, Giovanardi F, Strippoli A, Prisciandaro M, Di Donato S, Pompella L, Pecora I, Romagnani A, Fancelli S, Brugia M, Pillozzi S, De Vita F, Antonuzzo L. Giommoni E, et al. Among authors: sisani m. BMC Cancer. 2021 Oct 8;21(1):1086. doi: 10.1186/s12885-021-08768-7. BMC Cancer. 2021. PMID: 34625033 Free PMC article.
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
Bracarda S, Sisani M, Marrocolo F, Hamzaj A, Del Buono S, Altavilla A. Bracarda S, et al. Among authors: sisani m. Expert Rev Anticancer Ther. 2014 Nov;14(11):1283-94. doi: 10.1586/14737140.2014.965686. Epub 2014 Oct 29. Expert Rev Anticancer Ther. 2014. PMID: 25353258 Review.
Additive Manufactured Scaffolds for Bone Tissue Engineering: Physical Characterization of Thermoplastic Composites with Functional Fillers.
Sinha R, Sanchez A, Camara-Torres M, Uriszar-Aldaca IC, Calore AR, Harings J, Gambardella A, Ciccarelli L, Vanzanella V, Sisani M, Scatto M, Wendelbo R, Perez S, Villanueva S, Matanza A, Patelli A, Grizzuti N, Mota C, Moroni L. Sinha R, et al. Among authors: sisani m. ACS Appl Polym Mater. 2021 Aug 13;3(8):3788-3799. doi: 10.1021/acsapm.1c00363. Epub 2021 Aug 2. ACS Appl Polym Mater. 2021. PMID: 34476399 Free PMC article.
3D additive manufactured composite scaffolds with antibiotic-loaded lamellar fillers for bone infection prevention and tissue regeneration.
Cámara-Torres M, Duarte S, Sinha R, Egizabal A, Álvarez N, Bastianini M, Sisani M, Scopece P, Scatto M, Bonetto A, Marcomini A, Sanchez A, Patelli A, Mota C, Moroni L. Cámara-Torres M, et al. Among authors: sisani m. Bioact Mater. 2020 Oct 15;6(4):1073-1082. doi: 10.1016/j.bioactmat.2020.09.031. eCollection 2021 Apr. Bioact Mater. 2020. PMID: 33102947 Free PMC article.
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.
Bracarda S, Caserta C, Galli L, Carlini P, Pastina I, Sisani M, Scali S, Hamzaj A, Derosa L, Felici A, Rossi M, Altavilla A, Chioni A, De Angelis V. Bracarda S, et al. Among authors: sisani m. Future Oncol. 2015 Nov;11(22):3083-90. doi: 10.2217/fon.15.217. Epub 2015 Oct 5. Future Oncol. 2015. PMID: 26437324
12 results